Insider buying last 90 days
No open-market insider purchases were filed for BBIO in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BBIO insider filing, plotted on the chart in Gekko.Open BBIO in Gekko
NASDAQ: BBIO
BridgeBio Pharma (BBIO) Stock Analysis & Forecast
Sep 28 close
$66.61+1.04 (+1.6%)
Gekko Brief
AI summaryBridgeBio Pharma has drawn attention this week around Attruby, its ATTR-CM therapy, and its underlying compound acoramidis. Real-world study results reported reductions in early clinical worsening of 34% and diuretic intensification risk of 43% versus tafamidis, positioned against Pfizer's Vyndamax. Separately, the company outlined plans for four global product launches by 2027 as it moves beyond its current single commercial therapy, with commentary from President and CFO Thomas Trimarchi. Coverage this week has also debated the stock's fair value following the acoramidis study, alongside a note describing the shares as properly priced relative to its sales trajectory.
The stock closed at $66.61, up 1.6% on the day, though it remains below both its 50-day average of $77.58 and its 200-day average of $73.73, reflecting a mixed trend. Momentum has been negative over one month (-15.3%) and three months (-7.5%), while the one-year return stands at 35.9%. The GekkoIndex reads 72.3, placing it in the Buying zone, and the current price sits 26.2% below the Gekko Fair Value of $90.24.
The next earnings report is scheduled for 28 October 2026 after the close, 29 days out and beyond a typical 20-trading-day holding window; the prior report showed an EPS miss of -$0.78 versus -$0.58 estimated, with a -0.9% reaction. Options activity shows 1 unusual signal over the past 30 days, entirely put premium at $887,630 with no call premium. Seasonality over 5 years shows an average 20-day return of 3.3%, positive in 3 of those years. Analyst consensus stands at 16 buy ratings, 1 hold, with a consensus target of $109.1.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
BridgeBio Pharma price vs fair value
Close $66.61200-day averageGekko Fair Value $90.24
BridgeBio Pharma quick facts
- Market cap
- $13.05B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.56
- Revenue, TTM
- $713.1M
- Profit margin
- -97%
- Dividend yield
- —
- Beta
- 0.97
- Volume
- 2.93M avg 2.67M
- 1-year return
- +35.9%
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±10.1%
- 50-day average
- $77.58
- 200-day average
- $73.73
- Next earnings
- Oct 28 after close
- Shares outstanding
- 195.5M
BridgeBio Pharma swing-trade checklist
BridgeBio Pharma scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $66.61 sits between the 50-day ($77.58) and 200-day ($73.73) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
72.3, Buying
Reading 72.3 is in the Buying zone.
See the GekkoIndex - Fair valuesupportive
26.2% below
Price is 26.2% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyheadwind
Leans bearish
Last 30 days: 1 unusual options signal.
See smart money - Earnings risksupportive
Reports in 29 days
Next report Oct 28, 2026, 29 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+3.3% on average
From this point in the calendar, the next 20 trading days averaged +3.3% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
BridgeBio Pharma stock chart and price history
BridgeBio Pharma closed at $66.61 on Sep 28, 2026, +35.9% over the past year, inside a 52-week range of $48.88 to $93.42.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −15.3%
- 3 months
- −7.5%
- 6 months
- −4.4%
- 1 year
- +35.9%
The full BBIO chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BBIO in Gekko
Follow BridgeBio Pharma through every session
Put BBIO on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BBIO in GekkoFree for 7 days. No credit card required.
About BridgeBio Pharma
BridgeBio Pharma works on finding and developing treatments for genetic conditions, following candidates from early research through late-stage clinical testing. Its pipeline includes a small molecule meant to stabilize transthyretin for a heart condition tied to transthyretin amyloidosis, a molecule targeting a childhood bone-growth disorder, a gene transfer candidate for a hormonal condition affecting the adrenal glands, a compound aimed at a rare form of low blood calcium, and a program addressing recurring kidney stones and related hyperoxaluria. Some of these programs have reached mid to late-stage clinical trials, while others remain in earlier testing.
The company also pursues work in rare Mendelian disorders, cancer-related diseases, and gene therapy more broadly, running roughly thirty development programs at once. It carries out some of this work through licensing and collaboration arrangements with outside research institutions, including a major university, a state university system, and a biomedical research organization, which support parts of its scientific pipeline.
BridgeBio Pharma was established in 2015 and is headquartered in Palo Alto, California. Its shares are listed on the NASDAQ under the ticker BBIO.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- bridgebio.com
BridgeBio Pharma GekkoIndex: the smart money zone
BridgeBio Pharma’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 72.3, in the Buying zone, down 12.1 points over five sessions.
72.3Buying
Down 12.1 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying (current zone) | 27 | +1.8% | +4.5% | ||
| Accumulation | 182 | +1.3% | +3.6% | ||
| Neutral | 425 | +0.4% | +2.6% | ||
| Distribution | 36 | −0.1% | +0.4% | ||
| Selling | 2 | Too few readings yet | |||
Average BBIO share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Buying readings averaged +3.2% over 20 days. Past behaviour doesn’t guarantee future results.
Buying zone: Smart money likely accumulating heavily. About the five zones →
See every daily GekkoIndex reading plotted over the BBIO price, zone by zone.Track BBIO in Gekko
Is BridgeBio Pharma stock overvalued? Gekko Fair Value
BridgeBio Pharma trades 26.2% below Gekko Fair Value of $90.24, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what BridgeBio Pharma shares are worth, recalculated every trading day.
$90.24
Gekko Fair Value, Sep 25, 2026
26.2% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BBIO in Gekko
BridgeBio Pharma insider and Congress trading
No open-market insider purchases were filed for BridgeBio Pharma, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BBIO were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BBIO, plotted on the chart in Gekko.Open BBIO in Gekko
Buybacks
BridgeBio Pharma has been buying back its own shares.
- Latest authorization
- $500.0M, May 7, 2026
- Bought back, quarter ended Jun 30, 2026
- $127.5M
- As a share of market cap
- 0.98%
From company filings.
Unusual options activity last 30 days
1signal, 0% of the flagged premium in calls.
Latest: Bullish flow on Sep 16, $888K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds BBIO.
0added0opened1trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
BridgeBio Pharma earnings: next date and track record
BridgeBio Pharma reports on Oct 28, 2026, after the close (29 days away), and beat the EPS estimate in 1 of its last 8 reports.
Next earnings report
Oct 28, 2026
Expected after the close, 29 days away
- EPS estimate
- −$0.67
- Revenue estimate
- $269.0M
1 of 8reports beat the EPS estimate
±3.2%average move across the report
2 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 10, 2026 AI summary
- What they said
- BridgeBio reported continued commercial momentum for Attruby, the fastest-growing brand in ATTR-CM space at 23% quarterly growth. All three NDAs (LGMD2I/R9, ADH1, achondroplasia) were submitted with priority review granted for two programs and first PDUFA date set for November 27, 2026. The company completed a $1 billion preferred equity financing on July 1, 2026, supporting three upcoming launches. Management highlighted new kidney protection data for Attruby and a risk-adjusted revenue pipeline exceeding $10 billion.
- Guidance
- Management expects significant commercial acceleration for Attruby in the 6-9 month range driven by kidney protection data and real-world evidence. Three product launches are anticipated, with the first PDUFA date November 27, 2026. Chronic hypoparathyroid Phase 3 data expected within 18 months.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | −$0.78 est −$0.58 | $243.7M est $220.9M | −0.9% |
| May 7, 2026 | −$0.84 est −$0.62 | $194.5M est $178.1M | −1.0% |
| Feb 24, 2026 | −$0.94 est −$0.72 | $154.2M est $146.8M | −2.0% |
| Oct 29, 2025 | −$0.95 est −$0.88 | $120.7M est $148.2M | −1.8% |
| Aug 5, 2025 | −$0.95 est −$0.83 | $110.6M est $108.1M | −6.2% |
| Apr 29, 2025 | −$0.99 est −$0.89 | $116.6M est $68.41M | +6.9% |
| Feb 20, 2025 | −$1.37 est −$1.09 | $5.88M est $4.04M | +1.5% |
| Nov 12, 2024 | −$0.86 est −$0.98 | $2.73M est $67.32M | −5.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
BridgeBio Pharma stock forecast and analyst price targets
Analysts’ average 12-month price target for BridgeBio Pharma is $109.10, +63.8% from the last close, from 17 firms rating the stock in the last 90 days.
$109.10consensus 12-month target, +63.8% from the last close
Now $66.61Avg $109.10
Low $94High $157
Each firm’s latest rating in the last 90 days: 17 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 24 | TD Cowen | $110 | +65.1% |
| Sep 14 | Evercore ISI | $130 | +95.2% |
| Sep 10 | H.C. Wainwright | $120 | +80.2% |
| Sep 2 | H.C. Wainwright | $120 | +80.2% |
| Aug 31 | Barclays | $157 | +135.7% |
+4.5%average 20-day move after past Buying readings
+3.3%average move over the next 20 trading days in the last 5 years
±4.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
BridgeBio Pharma seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, BridgeBio Pharma averaged +3.3% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.6% | 3 of 5 |
| Next 10 trading days | +3.3% | 4 of 5 |
| Next 15 trading days | −0.6% | 2 of 5 |
| Next 20 trading days | +3.3% | 3 of 5 |
| Next 30 trading days | +7.1% | 4 of 5 |
For scale, BBIO’s typical 20-trading-day move in either direction is about 10.1%.
BridgeBio Pharma market cap and key statistics
BridgeBio Pharma’s market cap is $13.05B and revenue of $713.1M over the last twelve months.
Valuation
- Market cap
- $13.05B
- EPS, TTM
- −$3.56
- Gekko Fair Value
- $90.24
Trading
- Volume
- 2.93M
- Avg volume, 20 days
- 2.67M
- 52-week high
- $93.42
- 52-week low
- $48.88
- Shares outstanding
- 195.5M
Financials
- Revenue, TTM
- $713.1M
- Profit margin
- -97%
- Return on equity
- -1790%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.97
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±10.1%
BridgeBio Pharma stock news this week
Coverage of BridgeBio Pharma this week reads positive: 4 positive, 3 neutral and 3 negative headlines.
- BridgeBio Pharma (BBIO) Following Acoramidis Study Faces A Wide Fair Value DebateSimply Wall Street, Sep 27
- BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster StatusYahoo Finance, Sep 26
- BridgeBio Pharma (BBIO) Reports 34% Lower Risk Of Early Clinical WorseningSimply Wall Street, Sep 25
- BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum TranscriptSeeking Alpha, Sep 23
- BridgeBio says heart disease therapy Attruby beat Pfizer’s Vyndamax in real world studySeeking Alpha, Sep 23
- BridgeBio Pharma Announces Real-World Study Showing Acoramidis Reduced Clinical Worsening Versus Tafamidis in ATTR-CMQuiver Quantitative, Sep 23
BridgeBio Pharma peers
BridgeBio Pharma’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
BridgeBio Pharma stock FAQ
What is BridgeBio Pharma’s market cap?
BridgeBio Pharma’s market cap is $13.05B at the Sep 28, 2026 close of $66.61, with 195.5M shares outstanding.
What is the BridgeBio Pharma stock forecast?
The consensus analyst 12-month price target for BridgeBio Pharma is $109.10, +63.8% from the last close. Of the 17 firms that rated the stock in the last 90 days, 16 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is BridgeBio Pharma stock overvalued or undervalued?
On Gekko’s estimate BridgeBio Pharma is undervalued: the Sep 28, 2026 close of $66.61 is 26.2% below Gekko Fair Value of $90.24. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does BridgeBio Pharma report earnings next?
BridgeBio Pharma is expected to report on Oct 28, 2026, after the market closes (29 days away). Analysts expect earnings of −$0.67 per share on revenue of $269.0M. BridgeBio Pharma beat the earnings estimate in 1 of its last 8 reports, moving 3.2% on average across the report.
What is BridgeBio Pharma’s 52-week high and low?
BridgeBio Pharma’s 52-week high is $93.42 and its 52-week low is $48.88; it closed at $66.61 on Sep 28, 2026, +35.9% over the past year.
Is BridgeBio Pharma stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend) and 1 as a headwind (smart money). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in BridgeBio Pharma?
Gekko flagged 1 unusual options signal in BridgeBio Pharma over the last 30 days, with $0 of flagged premium in calls and $888K in puts. The latest, bullish flow, was on Sep 16, 2026 with $888K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See BridgeBio Pharma the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.